Kennedy Capital Management’s Atrium Therapeutics RNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$507K Buy
61,255
+26,276
+75% +$310K 0.01% 529
2026
Q2
$470K Buy
34,979
+1,002
+3% +$13.1K 0.01% 522
2026
Q1
$454K Buy
+33,977
New +$477K 0.01% 517

Other funds holding RNA

Kennedy Capital Management's RNA Position: Q3 2026 in Review

Kennedy Capital Management increased its Atrium Therapeutics (RNA) stake by 75% in Q3 2026, buying an estimated $310K and bringing the position to 61,255 shares worth $507K. The position accounts for 0.01% of the portfolio, ranked #529.

Kennedy Capital Management first reported a position in RNA in Q1 2026 and has held it in 3 quarters since. 145 funds tracked by Wall St. Rank hold RNA as of Q3 2026.

  • Kennedy Capital Management held 61,255 shares of Atrium Therapeutics worth $507K as of Q3 2026.
  • Kennedy Capital Management bought 26,276 Atrium Therapeutics shares in Q3 2026, an estimated $310K.
  • Atrium Therapeutics made up 0.01% of Kennedy Capital Management's portfolio in Q3 2026, its #529 holding.
  • Kennedy Capital Management first reported a position in Atrium Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • 145 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q3 2026.

Based on Kennedy Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.